Abstract
Historically, drug discovery was mainly focused on the development of so-called insulin sensitizers to address insulin resistance in type 2 diabetes. However, after scientists identified the failure and/or loss of pancreatic β‑cells as a cause for diabetes, research into the protection and regeneration of β‑cells gained increasing attention. Regenerative approaches under development include protecting β‑cells from stress-mediated cell death, augmenting β‑cell number, and improving their function. A number of molecular targets and drug candidates have been identified and validated in animal models. Novel, targeted therapies with curative potential are expected to enter the clinical phase in the medium term.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
